Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013–2018

Fig. 2

Cumulative incidence of tuberculosis (TB) in patients with rheumatoid arthritis (RA) who received biologic therapy. The cumulative incidence rate of TB was evaluated using the Kaplan–Meier method, and the differences among biologic therapies were compared using the log-rank test with multiple comparison adjustment. Infliximab showed a significantly higher risk of TB than etanercept (P = 0.04). The table shows the incidence rate of TB in patients with RA stratified by follow-up duration (< 0.5, 0.5–1, 1–3, and ≥ 3 years) CI, confidence interval

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us